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CASE REPORT
Non-convulsive status epilepticus induced by tiagabine
in a patient with pseudoseizure
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Tiagabine, a novel GABA reuptake inhibitor, has been reported to induce non-convulsive status epilepticus (NCSE) in patients
with epilepsy. We report a 27 year old female with history of pseudoseizure documented by video-EEG monitoring who
presented confusion while on 56 mg per day of tiagabine. Electroencephalography showed generalized sharp and slow wave
discharges, consistent with NCSE. The NCSE was terminated by lorazepam and did not recur after tiagabine was discontinued.
This case report suggests that tiagabine may induce NCSE in patients without epilepsy.
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INTRODUCTION
Tiagabine (TGB) has been approved as an add-
on antiepileptic drug therapy for partial seizures.
This medication appears to block neuronal and glial
reuptake of gamma-aminobutyric acid (GABA) and
thus increase synaptic GABA concentration1. In a
pre-marketing clinical trial, 0.8% (3/494) of patients
treated with TGB developed status epilepticus com-
pared with 0.7% (2/275) of placebo-treated patients2.
In 1996, Schapel and Chadwick reported three cases of
non-convulsive status epileptics (NCSE) in association
with 48–60 mg per day use of TGB3. Subsequent
reports4–6 demonstrate that NCSE occurred in patients
with partial onset and primary generalized seizures
when given TGB at a dose between 30 and 60 mg
per day. In the previously reported cases of NCSE, all
patients had epilepsy documented by EEG. Here we
report a case of TGB-induced NCSE in a patient with
documented pseudoseizure.
CASE REPORT
NT is a 27 years old African-American female.
At age 13, the patient developed typical events
that consisted of body thrashing, kicking, stiffening
followed by unresponsiveness for a few minutes
and a complete recovery. These events occurred
more frequently during stressful time periods and
interfered with her ability to work. The patient had
normal routine EEGs. She was then video-EEG-
monitored in 1992 and 1995 at university affiliated
EEG monitoring centers. On both occasions, her
typical events were captured on video and none
of these events had correlating EEG changes. The
patient saw multiple physicians and was given trials of
phenytoin, carbamazepine, valproic acid, gabapentin,
topiramate, and lamotrigine. She was subsequently
prescribed tiagabine and titrated to a total dose of
56 mg per day in the 3 months prior to admission.
After three weeks on the current dose, the patient
presented a 2 day history of intermittent confusion.
Physical examination at the time of admission showed
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Fig. 1: EEG recordings during non-convulsive status epilepticus.
normal vital signs. The patient was lethargic but
arousable, disoriented and slow in speech. Otherwise,
neurological examination was normal. Head CT at
the time of admission was unremarkable. Routine
laboratory studies (including renal and liver function
tests) showed no abnormality. Video-EEG monitoring
revealed generalized sharp and slow wave discharges
(Fig. 1), consistent with an ictal pattern of NCSE. The
patient was given 2 mg of lorazepam intravenously,
which was then repeated once within 10 minutes.
Her mental status significantly improved and her EEG
returned to normal. TGB was discontinued and the
patient was observed over the next 24 hours. During
the observation, she remained alert and oriented. She
then had two episodes of her typical events including
asynchronous body arching, thrashing, and avoidance
behavior that intermittently waxed and waned over
several minutes. These events had no corresponding
epileptiform changes on the EEG. Her neurological
examination was normal following each of these
events, and prolactin levels did not change when
measured 20 and 60 minutes following one event.
DISCUSSION
TGB has been known to induce NCSE in patients with
epilepsy3–6. In our patient, the patient had previously
documented pseudoseizures and developed NCSE
while on TGB. To our knowledge, this is the first
report that TGB induced NCSE in a patient without
epilepsy. The patient demonstrated, on three separate
video-EEG monitoring sessions at three different
university affiliated centers, episodes which were
concluded to be non-epileptic. The behavioral features
that lack a discrete end to the events and the absence
of both EEG changes and a rise in prolactin levels
suggested that the patient’s typical events were non-
epileptic. However, it should be acknowledged that the
patient might have true epilepsy that was not revealed
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by scalp EEG recordings. The NCSE induced by TGB
may be a manifestation of her underlying epilepsy. In
this sense, TGB may function as a diagnostic agent in
this patient.
The mechanism for TGB to induce NCSE is not
clear. GABA is a major inhibitory neurotransmitter
in the CNS. After its release from presynaptic
vesicles, GABA is taken back by GABA transporters
to presynaptic nerve terminals and glial cells. Four
types of GABA transporters in humans have been
identified, i.e. GAT-1, GAT-2, GAT-3, and BGT-1.
TGB appears to inhibit GAT-1 specifically with an
IC50 around 70 nM7. Inhibition of GABA reuptake
by TGB increases the synaptic concentration of
GABA, which in turn activates both GABAA and
GABAB receptors. Activation of presynaptic GABAB
receptors causes presynaptic inhibition that in turn
decreases further GABA release, i.e. an autoregulatory
mechanism. It has been postulated that TGB-induced
NCSE may be due to an inhibition of GABA release
by over-activation of presynaptic GABAB receptors4.
Over-activation of presynaptic GABAB receptors
by baclofen, a GABAB receptor agonist, has been
reported to induce NCSE8. However, TGB-induced
and baclofen-induced NCSE are not analogous. In the
presence of baclofen, synaptic GABA concentration
is not increased and postsynaptic GABAA receptors
are not highly activated. In contrast, in the presence
of TGB, synaptic GABA concentration is elevated and
postsynaptic GABAA receptors are highly occupied.
Therefore, it would be difficult to explain how NCSE
is developed in the presence of accumulated synaptic
GABA.
Pre-clinical studies have shown that TGB has a
weak affinity (IC50 = 15 000 nM) for benzodiazepine
receptors9. In a subset of patients, TGB at high
doses may non-specifically bind to and block benzo-
diazepine receptors. If this is the case, the situation
may be similar to seizures induced by flumazenil, an
antagonist of benzodiazepine receptors.
TGB may induce NCSE in patients with or without
epilepsy via the same mechanisms. Patients with
epilepsy may be more prone to TGB-induced NCSE
than those without epilepsy. However, the incidence of
TGB-induced NCSE in the non-epileptic population is
unknown. Like other AEDs, the use of TGB has been
extended to the non-epileptic patient population, e.g.
treating mood disorders10, headache, and spasticity.
One report has shown that TGB at 30 mg per
day induced generalized tonic–clonic seizure in a
patient with acute mania but no previous history of
epilepsy10. Therefore, it is important for physicians
to be aware that TGB may induce seizure in patients
without epilepsy.
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